Skip to main content
Top
Published in: Malaria Journal 1/2020

01-12-2020 | Malaria | Research

In silico analysis for factors affecting anti-malarial penetration into red blood cells

Authors: Natapol Pornputtapong, Bovornpat Suriyapakorn, Anchisa Satayamapakorn, Kanidsorn Larpadisorn, Pariyachut Janviriyakul, Phisit Khemawoot

Published in: Malaria Journal | Issue 1/2020

Login to get access

Abstract

Background

Malaria is a parasitic disease that produces significant infection in red blood cells. The objective of this study is to investigate the relationships between factors affecting the penetration of currently available anti-malarials into red blood cells.

Methods

Fifteen anti-malarial drugs listed in the third edition of the World Health Organization malaria treatment guidelines were enrolled in the study. Relationship analysis began with the prioritization of the physicochemical properties of the anti-malarials to create a multivariate linear regression model that correlates the red blood cell penetration.

Results

It was found that protein binding was significantly correlated with red blood cell penetration, with a negative coefficient. The next step was repeated analysis to find molecular descriptors that influence protein binding. The coefficients of the number of rotating bonds and the number of aliphatic hydrocarbons are negative, as opposed to the positive coefficients of the number of hydrogen bonds and the number of aromatic hydrocarbons. The p-value was less than 0.05.

Conclusions

Anti-malarials with a small number of hydrogen bonds and aromatic hydrocarbons, together with a high number of rotatable bonds and aliphatic hydrocarbons, may have a higher tendency to penetrate the red blood cells.
Literature
1.
go back to reference Wilairatana P, Tangpukdee N, Krudsood S. Update management of malaria and drug resistant malaria. Bangkok: Faculty of Tropical Medicine Mahidol University; 2016. p. 1–12. Wilairatana P, Tangpukdee N, Krudsood S. Update management of malaria and drug resistant malaria. Bangkok: Faculty of Tropical Medicine Mahidol University; 2016. p. 1–12.
2.
go back to reference WHO. Antimalarial drug combination therapy: report of a technical consultation. Geneva: World Health Organization; 2001. WHO. Antimalarial drug combination therapy: report of a technical consultation. Geneva: World Health Organization; 2001.
3.
go back to reference Li Q, Xie L, Haeberle A, Zhang J, Weina P. The evaluation of radiolabeled artesunate on tissue distribution in rats and protein binding in humans. Am J Trop Med Hyg. 2006;75:817–26.CrossRef Li Q, Xie L, Haeberle A, Zhang J, Weina P. The evaluation of radiolabeled artesunate on tissue distribution in rats and protein binding in humans. Am J Trop Med Hyg. 2006;75:817–26.CrossRef
4.
go back to reference Skinner T, Manning L, Johnston W, Davis T. In vitro stage-specific-sensitivity of Plasmodium falciparum to quinine and artemisinin drugs. Int J Parasit. 1996;26:519–25.CrossRef Skinner T, Manning L, Johnston W, Davis T. In vitro stage-specific-sensitivity of Plasmodium falciparum to quinine and artemisinin drugs. Int J Parasit. 1996;26:519–25.CrossRef
5.
go back to reference WHO. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015. WHO. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015.
6.
go back to reference Kim S, Thiessen P, Bolton E, Chen J, Fu G, Gindulyte A, et al. PubChem substance and compound databases. Nucleic Acids Res. 2015;44:D1202–13.CrossRef Kim S, Thiessen P, Bolton E, Chen J, Fu G, Gindulyte A, et al. PubChem substance and compound databases. Nucleic Acids Res. 2015;44:D1202–13.CrossRef
7.
go back to reference Winstanley P, Edwards G, Orme M, Breckenridge A. The disposition of amodiaquine in man after oral administration. Br J Clin Pharmacol. 1987;23:1–7.CrossRef Winstanley P, Edwards G, Orme M, Breckenridge A. The disposition of amodiaquine in man after oral administration. Br J Clin Pharmacol. 1987;23:1–7.CrossRef
8.
go back to reference Landrum G. RDKit: Open-Source Cheminformatics Software. 2019. Landrum G. RDKit: Open-Source Cheminformatics Software. 2019.
9.
go back to reference Friberg Hietala S. Clinical pharmacokinetics and pharmacodynamics of antimalarial combination therapy. Thesis: The Sahlgrenska Academy, University of Gothenburg; 2009. Friberg Hietala S. Clinical pharmacokinetics and pharmacodynamics of antimalarial combination therapy. Thesis: The Sahlgrenska Academy, University of Gothenburg; 2009.
10.
go back to reference Li Q, Milhous W, Weina P. Artemisinins in malaria therapy. New York: Nova Biomedical Books; 2007. Li Q, Milhous W, Weina P. Artemisinins in malaria therapy. New York: Nova Biomedical Books; 2007.
11.
go back to reference Wanwimolruk S, Edwards G, Ward S, Breckenridge A. The binding of the antimalarial arteether to human plasma proteins in-vitro. J Pharm Pharmacol. 1992;44:940–2.CrossRef Wanwimolruk S, Edwards G, Ward S, Breckenridge A. The binding of the antimalarial arteether to human plasma proteins in-vitro. J Pharm Pharmacol. 1992;44:940–2.CrossRef
12.
go back to reference Ali Z, Mishra N, Baldi A. Development and characterization of arteether-loaded nanostructured lipid carriers for the treatment of malaria. Artif Cells Nanomed Biotechnol. 2014;44:545–9.CrossRef Ali Z, Mishra N, Baldi A. Development and characterization of arteether-loaded nanostructured lipid carriers for the treatment of malaria. Artif Cells Nanomed Biotechnol. 2014;44:545–9.CrossRef
13.
go back to reference Gordi T. Clinical pharmacokinetics of the antimalarial artemisinin based if saliva sampling. PhD Dissertation, Acta Universitatis Upsaliensis, Uppsala; 2001. Gordi T. Clinical pharmacokinetics of the antimalarial artemisinin based if saliva sampling. PhD Dissertation, Acta Universitatis Upsaliensis, Uppsala; 2001.
15.
go back to reference Pharmaceutical Guilin. Summary of product characteristics: artesunate. Guangxi: Guilin Pharmaceutical; 2013. Pharmaceutical Guilin. Summary of product characteristics: artesunate. Guangxi: Guilin Pharmaceutical; 2013.
16.
go back to reference Gustafsson L, Walker O, Alvan G, Beermann B, Estevez F, Gleisner L, et al. Disposition of chloroquine in man after single intravenous and oral doses. Br J Clin Pharmacol. 1983;15:471–9.CrossRef Gustafsson L, Walker O, Alvan G, Beermann B, Estevez F, Gleisner L, et al. Disposition of chloroquine in man after single intravenous and oral doses. Br J Clin Pharmacol. 1983;15:471–9.CrossRef
17.
go back to reference Morris C, Duparc S, Borghini-Fuhrer I, Jung D, Shin C, Fleckenstein L. Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar J. 2011;10:263.CrossRef Morris C, Duparc S, Borghini-Fuhrer I, Jung D, Shin C, Fleckenstein L. Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar J. 2011;10:263.CrossRef
18.
go back to reference Wishart DS, Feunang YD, Marcu A, Guo AC, Liang K, et al. HMDB 4.0: the human metabolome database for 2018. Nucleic Acids Res. 2018;46:D608–17.CrossRef Wishart DS, Feunang YD, Marcu A, Guo AC, Liang K, et al. HMDB 4.0: the human metabolome database for 2018. Nucleic Acids Res. 2018;46:D608–17.CrossRef
19.
go back to reference Deshmukh P, Badgujar P, Gatne M. In-vitro red blood cell partitioning of doxycycline. Indian J Pharmacol. 2009;41:173.CrossRef Deshmukh P, Badgujar P, Gatne M. In-vitro red blood cell partitioning of doxycycline. Indian J Pharmacol. 2009;41:173.CrossRef
20.
go back to reference Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant J, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2017;46:D1074–82.CrossRef Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant J, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2017;46:D1074–82.CrossRef
21.
go back to reference Vieira J, Borges L, Ferreira M, Rivera J, Gomes M. Patient age does not affect mefloquine concentrations in erythrocytes and plasma during the acute phase of falciparum malaria. Braz J Infect Dis. 2016;20:482–6.CrossRef Vieira J, Borges L, Ferreira M, Rivera J, Gomes M. Patient age does not affect mefloquine concentrations in erythrocytes and plasma during the acute phase of falciparum malaria. Braz J Infect Dis. 2016;20:482–6.CrossRef
22.
go back to reference Hung T, Davis T, Ilett K. Measurement of piperaquine in plasma by liquid chromatography with ultraviolet absorbance detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;791:93–101.CrossRef Hung T, Davis T, Ilett K. Measurement of piperaquine in plasma by liquid chromatography with ultraviolet absorbance detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;791:93–101.CrossRef
23.
go back to reference Li Q, Hickman M. Pharmacokinetics and pharmacodynamics of antimalarial drugs used in combination therapy. Sharjah: Bentham Science Publisher; 2015.CrossRef Li Q, Hickman M. Pharmacokinetics and pharmacodynamics of antimalarial drugs used in combination therapy. Sharjah: Bentham Science Publisher; 2015.CrossRef
25.
go back to reference World Health Organization. Methods and techniques for assessing exposure to antimalarial drugs in clinical field studies. Geneva: World Health Organization; 2011. World Health Organization. Methods and techniques for assessing exposure to antimalarial drugs in clinical field studies. Geneva: World Health Organization; 2011.
27.
go back to reference Edstein M, Veenendaal J, Scott H, Rieckmann K. Steady-state kinetics of proguanil and its active metabolite, cycloguanil, in man. Chemotherapy. 1988;34:385–92.CrossRef Edstein M, Veenendaal J, Scott H, Rieckmann K. Steady-state kinetics of proguanil and its active metabolite, cycloguanil, in man. Chemotherapy. 1988;34:385–92.CrossRef
28.
go back to reference Rudy A, Poynor W. Binding of pyrimethamine to human plasma proteins and erythrocytes. Pharm Res. 1990;7:1055–60.CrossRef Rudy A, Poynor W. Binding of pyrimethamine to human plasma proteins and erythrocytes. Pharm Res. 1990;7:1055–60.CrossRef
30.
go back to reference Vieira J, Gomes A, Borges L, Guimarães E. Relationship between plasma and red blood cell concentrations of quinine in Brazilian children with uncomplicated Plasmodium falciparum malaria on oral therapy. Rev Inst Med Tropical de São Paulo. 2009;51:109–10.CrossRef Vieira J, Gomes A, Borges L, Guimarães E. Relationship between plasma and red blood cell concentrations of quinine in Brazilian children with uncomplicated Plasmodium falciparum malaria on oral therapy. Rev Inst Med Tropical de São Paulo. 2009;51:109–10.CrossRef
31.
go back to reference Berneis K, Boguth W. Distribution of sulfonamides and sulfonamide potentiators between red blood cells, proteins and aqueous phases of the blood of different species. Chemotherapy. 1976;22:390–409.CrossRef Berneis K, Boguth W. Distribution of sulfonamides and sulfonamide potentiators between red blood cells, proteins and aqueous phases of the blood of different species. Chemotherapy. 1976;22:390–409.CrossRef
32.
go back to reference Florey K. Analytical profiles of drug substances. San Diego: Academic Press; 1988. Florey K. Analytical profiles of drug substances. San Diego: Academic Press; 1988.
33.
go back to reference Grömping U. Relative importance for linear regression in R: the Package relaimpo. J Stat Softw. 2006;17:1–27.CrossRef Grömping U. Relative importance for linear regression in R: the Package relaimpo. J Stat Softw. 2006;17:1–27.CrossRef
34.
go back to reference Chen T, Guestrin C. XGBoost: a scalable tree boosting system. Proceedings of the ACM SIGKDD International Conference on Knowledge Discovery and Data Mining. 2016; 13-17-Augu. pp. 785–94. Chen T, Guestrin C. XGBoost: a scalable tree boosting system. Proceedings of the ACM SIGKDD International Conference on Knowledge Discovery and Data Mining. 2016; 13-17-Augu. pp. 785–94.
35.
go back to reference Akiba T, Sano S, Yanase T, Ohta T, Koyama M. Optuna: a next-generation hyperparameter optimization framework. Proceedings of the ACM SIGKDD International Conference on knowledge discovery and data mining. 2019. pp. 2623–31. Akiba T, Sano S, Yanase T, Ohta T, Koyama M. Optuna: a next-generation hyperparameter optimization framework. Proceedings of the ACM SIGKDD International Conference on knowledge discovery and data mining. 2019. pp. 2623–31.
36.
go back to reference Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, et al. Scikit-learn: machine learning in Python. J Mach Learning Res. 2011;12:2825–30. Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, et al. Scikit-learn: machine learning in Python. J Mach Learning Res. 2011;12:2825–30.
37.
go back to reference Lundberg S, Lee S-I. A unified approach to interpreting model predictions. Adv Neural Inform Processing Syst. 2017;2017:4766–75. Lundberg S, Lee S-I. A unified approach to interpreting model predictions. Adv Neural Inform Processing Syst. 2017;2017:4766–75.
39.
go back to reference Shibata N, Shimakawa H, Minouchi T, Yamaji A. Erythrocyte uptake and protein binding of cyclosporin A (CyA) in human blood: factors affecting CyA concentration in erythrocytes. Biol Pharm Bull. 1993;16:702–7.CrossRef Shibata N, Shimakawa H, Minouchi T, Yamaji A. Erythrocyte uptake and protein binding of cyclosporin A (CyA) in human blood: factors affecting CyA concentration in erythrocytes. Biol Pharm Bull. 1993;16:702–7.CrossRef
40.
go back to reference Kurata D, Wilkinson G. Erythrocyte uptake and plasma binding of di phenyl hydantoin. Clin Pharm Ther. 1974;16:355–62.CrossRef Kurata D, Wilkinson G. Erythrocyte uptake and plasma binding of di phenyl hydantoin. Clin Pharm Ther. 1974;16:355–62.CrossRef
41.
go back to reference Quinlan G, Martin G, Evans T. Albumin: biochemical properties and therapeutic potential. Hepatology. 2005;41:1211–9.CrossRef Quinlan G, Martin G, Evans T. Albumin: biochemical properties and therapeutic potential. Hepatology. 2005;41:1211–9.CrossRef
42.
go back to reference Samari F, Shamsipur M, Hemmateenejad B, Khayamian T, Gharaghani S. Investigation of the interaction between amodiaquine and human serum albumin by fluorescence spectroscopy and molecular modeling. Eur J Med Chem. 2012;54:255–63.CrossRef Samari F, Shamsipur M, Hemmateenejad B, Khayamian T, Gharaghani S. Investigation of the interaction between amodiaquine and human serum albumin by fluorescence spectroscopy and molecular modeling. Eur J Med Chem. 2012;54:255–63.CrossRef
43.
go back to reference Fagerholm U. Prediction of human pharmacokinetics—evaluation of methods for prediction of volume of distribution. J Pharm Pharmacol. 2007;59:1181–90.CrossRef Fagerholm U. Prediction of human pharmacokinetics—evaluation of methods for prediction of volume of distribution. J Pharm Pharmacol. 2007;59:1181–90.CrossRef
44.
go back to reference Ritchie T, Macdonald S, Young R, Pickett S. The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types. Drug Discov Today. 2011;16:164–71.CrossRef Ritchie T, Macdonald S, Young R, Pickett S. The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types. Drug Discov Today. 2011;16:164–71.CrossRef
Metadata
Title
In silico analysis for factors affecting anti-malarial penetration into red blood cells
Authors
Natapol Pornputtapong
Bovornpat Suriyapakorn
Anchisa Satayamapakorn
Kanidsorn Larpadisorn
Pariyachut Janviriyakul
Phisit Khemawoot
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2020
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/s12936-020-03280-y

Other articles of this Issue 1/2020

Malaria Journal 1/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.